Display options
Cite
Maleki M, Vakilian F, Amin A. Liver diseases in heart failure. Heart Asia. 2011;3(1):143-9doi: 10.1136/heartasia-2011-010023.
Maleki, M., Vakilian, F., & Amin, A. (2011). Liver diseases in heart failure. Heart Asia, 3(1), 143-9. https://doi.org/10.1136/heartasia-2011-010023
Maleki, Majid, et al. "Liver diseases in heart failure." Heart Asia vol. 3,1 (2011): 143-9. doi: https://doi.org/10.1136/heartasia-2011-010023
Maleki M, Vakilian F, Amin A. Liver diseases in heart failure. Heart Asia. 2011 Jan 01;3(1):143-9. doi: 10.1136/heartasia-2011-010023. eCollection 2011. PMID: 27326014; PMCID: PMC4898570.
Copy Download .nbib Format: NLM
Share it on

Heart Asia. 2011 Jan 01;3(1):143-9. doi: 10.1136/heartasia-2011-010023. eCollection 2011.

Liver diseases in heart failure.

Heart Asia

Majid Maleki, Farveh Vakilian, Ahmad Amin

Affiliations

  1. Department of Cardiology, Rajai Cardiovascular, Medical and Research Center, Tehran University of Medical Science, Tehran, Iran.
  2. Cardiology Department, Mashad University of Medical Science, Imam Reza Hospital, Mashad, Iran.
  3. Heart Failure and Transplantation, Rajai Cardiovascular, Medical and Research Center, Iran.

PMID: 27326014 PMCID: PMC4898570 DOI: 10.1136/heartasia-2011-010023

Abstract

Heart failure (HF) is a growing public health concern as a consequence of the ageing of the population and the improved survival of patients with HF. HF is defined as impaired organ perfusion and/or high filling pressure. It is a systemic and chronic disease and as such involves many organs, not least the liver and kidney. The complex vascular system of the liver and its high metabolic activity render it vulnerable to circulation disturbances and trigger many molecular and haemodynamic changes in patients. There are many studies describing the impact of liver disease on patient outcomes. Hepatic dysfunction is commonly seen in HF patients and is closely correlated with a poor outcome. Knowledge about the mechanisms and impacts of liver disease in HF helps us to know the stage of the disease and treat it properly. Moreover, many drugs and toxins that are metabolised in the liver and contribute to drug interactions should also be taken into account when prescribing medication for HF patients. In light of the above-mentioned points, the authors have compiled this review on congestive hepatopathy with the aim of providing physicians and cardiologists with a succinct and useful guide on the role of the liver in HF.

Keywords: Ventricular tachycardia; congenital heart disease; coronary artery disease; fallots tetralogy; heart failure treatment; heart failure with normal ejection fraction; risk stratification; systolic heart failure

References

  1. Circulation. 1950 Aug;2(2):286-97 - PubMed
  2. Int J Cardiol. 2010 Oct 8;144(2):321-2 - PubMed
  3. Eur J Intern Med. 2009 Jan;20(1):74-9 - PubMed
  4. Int Heart J. 2007 Mar;48(2):195-204 - PubMed
  5. Congest Heart Fail. 2011 Mar-Apr;17(2):80-4 - PubMed
  6. Arq Bras Cardiol. 2007 May;88(5):590-5 - PubMed
  7. J Card Fail. 2010 Jan;16(1):84-90 - PubMed
  8. Eur J Heart Fail. 2004 Aug;6(5):561-5 - PubMed
  9. Clin Liver Dis. 2002 Nov;6(4):947-67, viii-ix - PubMed
  10. Am J Cardiol. 2002 Dec 15;90(12 ):1405-9 - PubMed
  11. J Hepatol. 2010 Jul;53(1):179-90 - PubMed
  12. J Am Soc Echocardiogr. 2010 Jul;23 (7):685-713; quiz 786-8 - PubMed
  13. Am J Cardiol. 2003 Jun 1;91(11):1399 - PubMed
  14. Circulation. 1956 Mar;13(3):368-80 - PubMed
  15. Circ Heart Fail. 2009 Jul;2(4):294-302 - PubMed
  16. Circulation. 1989 Aug;80(2):299-305 - PubMed
  17. Circulation. 1958 Oct;18(4 Part 1):581-7 - PubMed
  18. Hepatology. 1996 Aug;24(2):451-9 - PubMed
  19. Heart. 2002 Jan;87(1):9-15 - PubMed
  20. J Clin Invest. 1953 Oct;32(10):1025-33 - PubMed
  21. Ann Hepatol. 2006 Jul-Sep;5(3):132-9 - PubMed
  22. Int J Cardiol. 2008 Jul 4;127(2):271-3 - PubMed
  23. Circ Heart Fail. 2010 Jan;3(1):59-64 - PubMed
  24. Circulation. 1951 Apr;3(4):501-7 - PubMed

Publication Types